Roche's etrolizumab meets primary endpoint of clinical remission in moderate to severely active ulcerative colitis at week 10
Roche announced today that the EUCALYPTUS phase II induction study of etrolizumab in patients with moderate-to-severely active ulcerative colitis (UC) met its primary endpoint of clinical remission at week 10. Additionally, the data showed etrolizumab was well tolerated with no clinically significant safety concerns. Findings were presented this weekend at the 2013 Digestive Disease Week meeting held in Orlando, Fla.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news